Abstracts tagged "Co-morbidities and psoriatic arthritis"

Abstract Number: 2746 • 2016 ACR/ARHP Annual Meeting
Comparing Prevalence of Comorbidities in Patients with Psoriatic Arthritis By Biologic Therapy
Jeffrey Kaine¹, Xue Song², Gilwan Kim² and Jacqueline Palmer³, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Truven Health Analytics, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) are known to be at higher risk for numerous comorbid conditions. This study looks at the impact of biologic therapy…
Abstract Number: 2771 • 2016 ACR/ARHP Annual Meeting
Higher Incident Rates of Comorbidities in Patients with Psoriatic Arthritis (PsA) Compared to Controls
Jeffrey Kaine¹, Xue Song², Gilwan Kim² and Jacqueline Palmer³, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Truven Health Analytics, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: PsA is associated with higher rates of developing certain comorbidities, but little has been done to understand the incidence rates of comorbidities in…
Abstract Number: 1547 • 2014 ACR/ARHP Annual Meeting
Endocrine Co-Morbidities in Patients with Psoriatic Arthritis: A Population-Based Study
Devy Zisman^1,2, Ron Ilan Ashkenazi³, Haim Bitterman^4,5, Guy Shallom⁶, Ilan Feldhamer⁶, Idit Lavi⁷, Sari Greenberg-Dotan⁶ and Arnon-Dov Cohen⁶, ¹Dept of Internal Medicine, Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁵Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ⁶Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁷Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel
Background/Purpose: Co-morbidities associated with psoriatic arthritis (PsA) include cardiovascular, ophthalmic and gastrointestinal diseases. The aim of the study was to investigate endocrine co-morbidities in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].